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Abstract
Aims To determine the magnitude of morbidity from asthma within the New Zealand
population, the degree of satisfaction of patients with their asthma control, and the
level of asthma control achieved in relation to treatment.
Methods Participants were randomly selected from 29 randomly chosen general
practices throughout New Zealand. Information was collected from demographic and
clinical questionnaires and from lung function tests. Criteria based on GINA
guidelines were developed to define the level of asthma control for each participant,
their opinion of their level of control, and to define which participants were under-
treated.
Results  A total of 445 patients (327 adults, age 16–68; 118 children, age 7–15) took
part in the study. Ninety three per cent of adults had asthma that was sub-optimally
controlled, 71% had asthma that was not well controlled, and 19% had asthma that
was markedly out of control. For children, these figures were 90%, 42% and 4%
respectively. These results were consistent regardless of asthma severity. In adults and
children whose asthma was not well controlled, 49% and 71% respectively were
under-treated. For those whose asthma was markedly out of control, 89% and 75% of
adults and children respectively were under-treated.
Conclusions  A significant proportion of patients have asthma that is not well
controlled or that is markedly out of control, and the majority are under-treated.
Asthma is one of the most common chronic diseases in New Zealand and is the most
common cause of hospital admission in children.1,2 New Zealand has one of the
highest prevalence rates of asthma,3–5 with Maori, Pacific Islanders and low
socioeconomic groups disproportionately affected.6,7 A recent publication by the
Asthma and Respiratory Foundation of New Zealand has estimated the medical and
economic costs of asthma in New Zealand to be over $800 million every year.8
The burden of asthma throughout the world in terms of morbidity, mortality and
economic cost is considerable.9 Recent community-based surveys in Europe, the
United States and the Asia-Pacific regions have shown that the level of asthma control
usually falls far short of the recommended goals.10–12 For example, throughout these
regions, around 30% of patients with asthma reported waking with breathing
problems at least once a week. Also, over 40% of children with asthma had missed
school and over 20% of adults with asthma had missed work within the previous 12
months due to their condition. Furthermore, over one third of individuals with asthma
were either hospitalised, treated in an emergency department or required other urgent
care for their asthma in the previous 12 months.
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These findings contrast with the goals of asthma management described in the GINA
(Global Initiative for Asthma) guidelines:9
· minimal (ideally no) chronic symptoms, including nocturnal symptoms;
· minimal (infrequent) episodes;
· no emergency visits;
· minimal need for reliever medication;
· no limitations on activities including exercise;
· have normal or near-normal lung function (peak expiratory flow variability
<20%).
Only 5% of asthmatics surveyed in seven countries in Europe met all of these goals.10
The Patient Outcomes Management Survey (POMS) was undertaken in New Zealand
in 2001 in order to assess the magnitude of the morbidity from asthma in the
population, to assess the level of asthma control in a randomly selected sample of
adults and children from a general practice setting, and to correlate these findings to
the treatment received.
Methods
This was a multi-centre, national study of asthma control, performed in a general practice setting. Data
were collected from 327 adults and 118 children from 29 general practices chosen randomly from
across New Zealand.
A computer programme was used to place all practices in New Zealand in a random order. Practices
were then approached sequentially and invited to take part until a sufficient number had agreed. The
aim was to recruit 400–500 patients, adult or children, from approximately 30 general practices, but
this was not based on formal power calculations.
In each practice, asthmatic patients who had been prescribed medication for asthma in the previous
year were randomly chosen from computer or paper-based records and invited to participate until
approximately 15 patients had been recruited. The definition of asthma used was ‘doctor diagnosis of
asthma’. There are many definitions and diagnostic criteria for asthma, but no gold standard. ‘Doctor
diagnosis’ is easy to use and has a high specificity and positive predictive value.
For each participant in the survey, the following data were collected:
· age, sex, ethnicity and smoking status;
· asthma symptom frequency, resource utilization, usual management and knowledge about asthma;
· the Asthma Quality of Life Questionnaire for adults and the Paediatric Quality of Life
Questionnaire for children;13,14
· the highest of three pre-bronchodilator FEV1 (forced expiratory volume in one second)
measurements.
Morning, day and night symptom frequency were recorded as: never; 1–2 times a month; 1–2 times a
week; or every day. Activity-induced asthma was classified as: rarely; with exercise or sports; with
hills, stairs or active play; or with walking on the flat.
Participants were classified according to their prescribed treatment step in the British Guidelines of
Asthma Management (BGAM):15
· Step 1: inhaled short-acting bronchodilator only (used in all five steps)
· Step 2: 0–799 µg inhaled corticosteroid (ICS) [all doses are µg/day beclomethasone dipropionate
(BDP) or equivalent] or cromoglycate
· Step 3: ³ 800 µg ICS or 0–799 µg ICS plus long-acting ß-agonist (LABA) or other (formoterol,
salmeterol, leukotriene receptor antagonist, theophylline ipratropium, b2-agonist tablets)
· Step 4: ³ 800 µg plus LABA or other
· Step 5: oral steroids for at least one month
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In the analysis, a child was defined as 7–15 years of age inclusive. Data analysis was undertaken using
Microsoft Excel and SAS. Ethics committee approval was obtained for the study from all New Zealand
Ethics Committees.
Definitions of asthma control and under-treatment The only globally standardized criteria for
asthma control are those of the GINA guidelines described above. However, for the vast majority of
patients with asthma, this level of control is unrealistic. Therefore, two further criteria of control were
developed, based on the frequency and severity of symptoms and lung function (Table 1). These
criteria were developed for the purposes of this study and therefore require further validation.
Table 1. Definition of asthma control in patients whose asthma was sub-
optimally controlled, not well controlled, or markedly out of control
Sub-optimal control
(at least 1 of the
following)
Not well controlled
(at least 2 of the
following)
Markedly out of control
(at least 3 of the
following)
Early-morning
symptoms
³ Weekly ³ Weekly ³ Daily
Day symptoms ³ Weekly ³ Daily ³ Daily
Night symptoms ³ Weekly ³ Weekly ³ Nightly
Asthma induced by: Exercise/sports Hills/stairs/active play Walking on flat
FEV1 <80% predicted <80% predicted <70% predicted
Use of reliever 1–2 times/day 1–2 times/day ³3 times/day
‘Sub-optimal control’ equates to a patient not achieving a level of control similar to that described in
the GINA guidelines, ie, not optimally controlled. For a classification of ‘not well controlled’ at least
two of the listed goals must be breached; for example, this definition will not include those who use
their reliever inhaler out of habit or as a prophylactic before exercise. Finally, the definition of
‘markedly out of control’ represents a level of symptoms that would cause a major interference in the
patient’s life. ‘Not well controlled’ and ‘markedly out of control’ are subsets of ‘sub-optimal control’,
and ‘markedly out of control’ is a subset of ‘not well controlled’.
Further, the proportion of each group who were under-treated was estimated.
Patients classified as not well controlled were considered to be adequately treated if they received
either:
1. ICS ³800 µg/day (beclomethasone dipropionate or equivalent); or
2. ICS <800 µg/day and a LABA.
Patients classified as markedly out of control were considered to be adequately treated if they received:
1. ICS ³800 µg/day; and
2. LABA.
It should be noted that for both groups an increase in treatment may not necessarily lead to clinical
improvement but that the level of symptoms experienced warrants that increase.
Results
Three hundred and twenty seven adults and 118 children from 29 general practices
took part in the survey. Eighty three per cent of practices that were approached agreed
to take part and approximately 75% of patients who were approached by their practice
opted to take part in the study. The demographics of the participants and their
classification with the BGAM steps are presented in Table 2.
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Table 2. Patient demographics
Characteristic Adults Children
Gender
Male
Female
39%
61%
58%
42%
Age (mean, range, SD) 36.7 (16–68, ± 11.1) 10.6 (7–15, ± 2.4)
Smoking status
Current smokers
Ex-smokers
Non-smokers
27%
20%
53%
0%
1%
99%
Ethnicity
Pakeha
Maori
Other
68%
9%
23%
61%
10%
30%
BGAM step
Step 1
Step 2
Step 3
Step 4
Step 5
10%
47%
38%
5%
1%
9%
65%
20%
5%
0%
BGAM = British Guidelines of Asthma Management
NB: some percentages do not add up to 100 due to rounding
The proportions of those classified as either sub-optimally controlled, not well
controlled, or markedly out of control were compared to BGAM step (Table 3).
Table 3. Level of asthma control according to the British Guidelines of Asthma
Management (BGAM) in adults and children (NB: ‘not well controlled’ and
‘markedly out of control’ are subsets of ‘sub-optimal control’, and ‘markedly out of
control’ is a subset of ‘not well controlled’)
Adults (%) Children (%)BGAM Step
Sub-
optimal
control
Not well
controlled
Markedly
out of
control
Sub-
optimal
control
Not well
controlled
Markedly
out of
control
1 90 57 10 100 30 0
2 88 66 13 90 44 3
3 98 82 26 83 48 4
4 100 82 35 100 50 17
5 100 100 100
Total 93 71 19 90 42 4
Data on the use of health services for asthma and the impact of asthma on work and
school are outlined in Table 4. This table also includes some important findings from
the questionnaires, including time off school or work, contacts with health services
and satisfaction with asthma control.
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Table 4. Key results from the questionnaires
Adults (%) Children (%)
Days missed from work or school in the last month
0
1–2
>2
90
7
3
88
6
6
GP contact in the last 3 months
Scheduled appointment
Unscheduled appointment
Phone contact
Contact with GP after hours
39
6
14
5
31
6
11
16
Hospital admission in last 12 months
Emergency department
Hospital admission
Intensive care unit
7
2
0.06
12
2
0.90
Is your asthma well controlled?
Yes
No
Do not know
76
16
8
76
8
16
Are you satisfied with your level of asthma control?
Yes
No
Do not know
80
19
1
85
14
1
Do you have a written asthma management plan?
Yes 36 40
Do you have a peak flow meter?
Yes 72 72
The use of medication in those patients whose asthma was not well controlled or
markedly out of control is presented in Table 5.
Table 5. Medication use by patients whose asthma was not well controlled or was
markedly out of control
Patients (n) No ICS
No
LABA
n (%)
ICS <800
No
LABA
n (%)
ICS ³800
No
LABA
n (%)
ICS <800
+ LABA
n (%)
ICS ³800
+ LABA
n (%)
Under-
treated
n (%)
Adults (327)
Not well controlled (233)
Markedly out of control (61)
20 (9)
5 (8)
94 (40)
17 (28)
95 (41)
31 (51)
8 (3)
1 (2)
16 (7)
7 (11)
114 (49)
54 (89)
Children (128)
Not well controlled (49)
Markedly out of control (4)
4 (8)
0 (0)
31 (63)
2 (50)
11 (22)
1 (25)
0 (0)
0 (0)
3 (6)
1 (25)
35 (71)
3 (75)
All ICS doses are µg/day beclomethasone dipropionate or equivalent
ICS = inhaled corticosteroid; LABA = long-acting ß-agonist
Finally, the proportion of each group who were under-treated was estimated according
to the method described above. Those who are considered to be under-treated are
represented in bold in Table 5.
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Discussion
This study represents a snapshot of current asthma morbidity and management in New
Zealand. The major finding was that a majority of adults and children with asthma
were not well controlled according to the criteria used. This applied across all BGAM
steps, implying that patients across the spectrum of asthma severity were not well
controlled. The results are comparable to those observed in similar studies conducted
overseas.
A possible selection bias may have occurred in that only patients who had been
prescribed asthma medication in the previous year were invited to take part. This
could have resulted in the exclusion of a small subset of very mild asthmatics but this
is unlikely to have had a significant impact on the findings.
The definitions of asthma control used in this study have been adapted from the GINA
guidelines to capture the spectrum of asthma control levels. It would have been hoped
that more than around 10% of adults and children would have achieved a better level
of control than the sub-optimal control criteria. Furthermore, the findings that 72% of
adults and 44% of children have asthma that is not well controlled are unexpectedly
high and it is of great concern that around one fifth of adults and one twentieth of
children fall within the category of markedly out of control.
The findings of this study highlight some of the costs of poor asthma control. Around
10% of asthmatics had missed school or work in the previous month due to their
condition. In the previous three months, two thirds of adults and children had
contacted a GP about their asthma, often out of hours, and about 10% had been to the
emergency department or had been admitted to hospital with asthma in the previous
year.
Some of the most important findings from this study were those concerning patients’
expectations about their condition and management. There was a striking mismatch
between the patients’ perception of asthma control and the actual level of control as
defined in this study. Overall, 76% thought that their asthma was well controlled and
80% were satisfied with their level of control. It would appear that, despite significant
symptoms, these patients considered themselves to be ‘normal’ for a person with
asthma. It would follow that these symptoms may not be reported to their doctor. This
emphasises the need for diligent assessment of patients with asthma at each clinic
visit.
In addition, despite their simplicity and proven effectiveness, only 36% of patients
had a written asthma management plan.16
It was beyond the scope of this study to assess patient compliance with treatment.
Compliance with treatment for chronic conditions is often poor, usually due to the
dislike of having to take medications continuously or the fear of side effects.
Finally, this survey has revealed that for those whose asthma is not well controlled,
49% of adults and 71% of children are under-treated. For those whose asthma is
markedly out of control, 89% of adults and 75% of children are under-treated. Whilst
it was beyond the scope of this study to determine the reasons for this degree of
under-treatment, a possible explanation includes the mismatch in patients’ perception
of asthma control and actual control. The widespread under-treatment that was seen
may in part be due to local restrictions placed on the prescribing of newer medications
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such as long-acting ß-agonist drugs and the inhaled corticosteroid/long-acting ß-
agonist combinations. It is also likely that problems in accessing GP care have
contributed to this level of under-treatment.
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